Imunon, Inc. Operating Income Loss

• Imunon, Inc. showed an increase of +23.4% in Operating Income Loss from 2024 to 2025.
• This data is from Imunon, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), Imunon, Inc.'s Operating Income Loss has grown by 25.4%.
• Historical annual values: Fiscal year 2025: -$14.65 million | Fiscal year 2024: -$19.13 million | Fiscal year 2023: -$21.03 million | Fiscal year 2022: -$24.92 million | Fiscal year 2021: -$21.01 million | Fiscal year 2020: -$18.49 million | Fiscal year 2019: -$20.57 million | Fiscal year 2018: -$21.07 million | Fiscal year 2017: -$18.47 million | Fiscal year 2016: -$20.65 million | Fiscal year 2015: -$20.85 million | Fiscal year 2014: -$24.72 million | Fiscal year 2013: -$15.41 million | Fiscal year 2012: -$22.14 million | Fiscal year 2011: -$23.02 million | Fiscal year 2010: -$19.64 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026